Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera PTG-300 treatment demonstrates robust clinical response and provides clinically meaningful dose related control of hematocrit values on individual patient basis Results to be presented today by Ronald Hoffman, M.D., Director of the Myeloproliferative Diseases Program at The Icahn […]
PV Reporter Attends MPN Horizons 2019, 4th Annual Global Conference
4th year in Attendance by David Wallace On October 25th, 2019 approximately 50 MPN advocates representing over 25 advocacy groups from around the world met in Lisbon, Portugal for 3 days. The objective was to share best practices of support and advocacy activities, learn about new MPN research and discuss issues that patients in each […]
A thrombopoietin receptor antagonist is capable of depleting MF hematopoietic stem and progenitor cells
The following abstract involved the work of Dr Ron Hoffman, the principle investigator (PI), senior member of the MPN group at Mt Sinai Hospital in New York City as well as the PI of the MPN-RC. Xiaoli Wang, Phd, performed all of the lab work. Dr John Mascarenhas was my point of contact for this […]
MPN Clinical Trial Highlights for Summer 2015
by mpdsupport.org Clinical Trials for MPNs are on the Rise! If you have MF, PV or ET but don’t need medication now, you may think that clinical trials don’t matter to you. But that could change, at which point you may want to review your options. Thankfully, over the past years the interest in developing […]
Geron’s Clinical Trials of Imetelstat put on Hold
FDA asks Geron to Halt Development of Imetelstat The FDA has placed it’s only pipeline candidate, imetelstat, on full clinical hold. The news sent shares of GERN plunging 61% on March 12, 2014. Geron had submitted an Investigation New Drug (IND) application for imetelstat, but the FDA issued a verbal notice halting the trials. This […]
